Central pharmacodynamic activity of solanezumab in mild Alzheimer's disease dementia.

ABSTRACT:

Introduction

Solanezumab treatment was previously shown to significantly increase total (bound + unbound) cerebrospinal fluid (CSF) levels of amyloid β (Aβ)_1-40 and Aβ_1-42 in patients with mild to moderate Alzheimer's disease dementia yet did not produce meaningful cognitive effects. This analysis assessed solanezumab's central nervous system target engagement by evaluating changes in CSF total and free Aβ isoforms and their relationship with solanezumab exposure.

Methods

CSF Aβ isoform concentrations were measured in patients with mild Alzheimer's disease dementia from a pooled EXPEDITION + EXPEDITION2 population and from EXPEDITION3. CSF solanezumab concentrations were determined from EXPEDITION3.

Results

Solanezumab produced statistically sign

SUBMITTER: Willis BA 

PROVIDER: S-EPMC6258891 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature